Advances in pediatric asthma and atopic dermatitis

Current Opinion in Pediatrics

Volumn 17, Issue 5, 2005, Pages 658-663

  Foroughi, Shabnam ^a   Thyagarajan, Ananth ^b   Stone, Kelly D ^b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Section of Allergy and Immunology   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allergic rhinitis; Asthma; Atopic dermatitis; Corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CROMOGLYCATE DISODIUM; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PIMECROLIMUS; SALBUTAMOL; SHORT ACTING DRUG; TACROLIMUS;

AIR POLLUTION; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; BACTERIAL INFECTION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; LUNG DEVELOPMENT; LYMPHOMA; MAINTENANCE THERAPY; META ANALYSIS; METERED DOSE INHALER; MIDDLE EAR; MILK ALLERGY; NEBULIZER; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; LYMPHOMA; NEBULIZERS AND VAPORIZERS;

EID: 26044479422     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000178386.61932.0b     Document Type: Review

References (43)

1. Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004; 145:172-177.
2. Smyth RL, Jones A. Treatment of acute wheezing episodes in young children. J Pediatr 2004; 145:151-152.
3. Bollinger ME, Wolf B, Schwindt C, Hamilton RG. Contamination of nebulizer equipment with cockroach allergen: there's a bug in the system! Ann Allergy Asthma Immunol 2004; 92:475-477. This interesting paper demonstrates the importance of looking for allergen exposure in unexpected places. Detective work is frequently needed to ensure optimal care for our patients.
4. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004; 126:1134-1137.
5. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-1396.
6. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48:134-138.
7. Wahedna I, Wong CS, Wisniewski AF, et al. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis 1993; 148: 707-712.
8. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841-847.
9. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355:1675-1679.
10. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512. This important study demonstrates that a genetic polymorphism in the β-adrenergic receptor alters clinical responsiveness to albuterol, leading to diminished asthma control. It also demonstrates that ipratropium bromide may be effective as a treatment for asthma exacerbations in patients with the described polymorphism. Characterization of a patient's genotype for specific genes should allow customization of treatment strategies (the pharmacogenetic approach).
11. Israel E. Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol 2005; 115:8532-8538.
12. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002; 110:8141-8219.
13. Berger WE, Shapiro GG. The use of inhaled corticosteroids for persistent asthma in infants and young children. Ann Allergy Asthma Immunol 2004; 92:387-399 quiz 399-402, 463.
14. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999; 160:126-131.
15. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87:457-461.
16. De Swert LF, Wouters C, de Zegher F. Myopathy in children receiving high-dose inhaled fluticasone. N Engl J Med 2004; 350:1157-1159.
17. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107:461-468.
18. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242. This important study demonstrated that an inhaled corticosteroid is more effective than a leukotriene antagonist as a maintenance asthma therapy for atopic children with allergic inflammation and diminished lung function.
19. Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003; 111:57-65.
20. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138:694-698.
21. Nowak-Wegrzyn A, Shapiro GG, Beyer K, et al. Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J Allergy Clin Immunol 2004; 113:558-560.
22. Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004; 113:86-93.
23. Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004; 113:415-419.
24. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Correlation of nasal inflammation and nasal airflow with forced expiratory volume in 1 second in patients with perennial allergic rhinitis and asthma. Ann Allergy Asthma Immunol 2004; 93:575-580.
25. Nguyen LH, Manoukian JJ, Sobol SE, et al. Similar allergic inflammation in the middle ear and the upper airway: evidence linking otitis media with effusion to the united airways concept. J Allergy Clin Immunol 2004; 114:1110-1115.
26. Rich M, Lamola S, Amory C, Schneider L. Asthma in life context: video intervention/prevention assessment (VIA). Pediatrics 2000; 105:469-477.
27. Gergen PJ, Mortimer KM, Eggleston PA, et al. Results of the National Cooperative Inner-City Asthma Study (NCICAS) environmental intervention to reduce cockroach allergen exposure in inner-city homes. J Allergy Clin Immunol 1999; 103:501-506.
28. Htut T, Higenbottam TW, Gill GW, et al. Eradication of house dust mite from homes of atopic asthmatic subjects: a double-blind trial. J Allergy Clin Immunol 2001; 107:55-60.
29. Rijssenbeek-Nouwens LH, Oosting AJ, de Bruin-Weller MS, et al. Clinical evaluation of the effect of anti-allergic mattress covers in patients with moderate to severe asthma and house dust mite allergy: a randomised double blind placebo controlled study. Thorax 2002; 57:784-790.
30. Woodcock A, Forster L, Matthews E, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349:225-236.
31. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351:1068-1080. This very important paper from the Inner City Asthma Consortium demonstrates that effective environmental controls result in significant improvement in asthma control. The key is to be thorough in environmental assessment and to address multiple environmental exposures.
32. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054-1063.
33. Cabana MD, Slish KK, Lewis TC, et al. Parental management of asthma triggers within a child's environment. J Allergy Clin Immunol 2004; 114:352-357.
34. Trasande L, Thurston GD. The role of air pollution in asthma and other pediatric morbidities. J Allergy Clin Immunol 2005; 115:689-699.
35. Kim JJ. Ambient air pollution: health hazards to children. Pediatrics 2004; 114:1699-1707. This important practice parameter from the American Academy of Pediatrics reviews the effects of pollution on developing children and urges revision of current air quality standards.
36. Gauderman WJ, Avol E, Gilliland F, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004; 351:1057-1067.
37. This important paper demonstrates loss of lung function associated with exposure to air pollution. This further supports the recommendations presented by Kim (Pediatrics 2004; 114:1699).
38. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:8118-8127.
39. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856-860.
40. Reuveni H, Chapnick G, Tal A, Tarasiuk A. Sleep fragmentation in children with atopic dermatitis. Arch Pediatr Adolesc Med 1999; 153:249-253.
41. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004; 93:81-21. This is a thorough presentation outlining all aspects of atopic dermatitis care.
42. Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr 2003; 15: 399-404.
43. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115:1249-1253. This important analysis should be reviewed by all pediatricians caring for children with atopic dermatitis.